Sofosbuvir: an all-around drug in hepatitis C treatment new era – The first phase
DOI:
https://doi.org/10.7175/rhc.v6i2.1164Keywords:
Chronic hepatitis C virus, Sofosbuvir, Protease inhibitorAbstract
Chronic hepatitis C virus (HCV) infection is a slowly progressive disease affecting more than 185 million people worldwide. For many years, the combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been the backbone of treatment for patients infected with HCV. More than two years ago, the first generation direct-acting antiviral agents (DAAs) – the protease inhibitors boceprevir and telaprevir – were approved for treatment of genotype 1 patients, doubling the cure rate. The new DAAs that have been developed, are effective for multiple genotypes, improve rates of sustained viral response with fewer side effects, simplify dosing and drug-drug interactions, and in some patients, offer the promise of interferon-free and/or ribavirin-free therapy. These new agents include the recently approved second generation protease inhibitor, the HCV NS5B polymerase inhibitor sofosbuvir and the NS3/4A protease inhibitor simeprevir as well as several other agents that are currently in later phases of development. With sofosbuvir-based regimens, successful interferon-free treatment is now available across all genotypes. In fact sofosbuvir is very effective in combination with Peg-interferon and ribavirine or with ribavirine alone or with other direct anti-viral agents. The following assessment evaluates the evidence on the clinical effectiveness and harms of sofosbuvir for the treatment of chronic hepatitis C.
References
Sovaldi™ – Riassunto delle Caratteristiche di Prodotto
Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, 2012
Gane EJ, Robson RA, Bonacini M, et al. Safety, Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Lawitz E, Rodriguez-Torrez M, Cornpropst M, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, 2012
Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2012
Denning J, Cornpropst M, Clemons D, et al. Lack of effect of the nucleoside analog polymerase inhibitor PSI-7977 on methadone PK and PD. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, 2011
Gane E, Stedman C, Hyland R, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Rodriguez-Torres M, Lawitz E Kowdley K, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58: 663-8; http://dx.doi.org/10.1016/j.jhep.2012.11.018
Lawitz E, Lalezari J, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8; http://dx.doi.org/10.1016/S1473-3099(13)70033-1
Gane E, Stedman C, Hyland R, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44; http://dx.doi.org/10.1056/NEJMoa1208953
Kowdley K, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7; http://dx.doi.org/10.1016/S0140-6736(13)60247-0
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87; http://dx.doi.org/10.1056/NEJMoa1214853
Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77; http://dx.doi.org/10.1056/NEJMoa1214854
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001; http://dx.doi.org/10.1056/NEJMoa1316145
Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, DC, 2013
Ruane PJ1, Ain D2, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2014 [Epub ahead of print]; http://dx.doi.org/10.1016/j.jhep.2014.10.044
Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7; http://dx.doi.org/10.1053/j.gastro.2014.09.023
Samuel, M Charlton, E Gane, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). London, 2014
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65; http://dx.doi.org/10.1016/S0140-6736(14)61036-9
Aqel B, Pungpapong S, Werne KTr, et al. The use of simeprevir and sofosbuvir to treat HCV G1 in the Liver Transplant Setting: The experience in 3 US Centers. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Pungpapong S, Werner KT, Aqel B, et al. Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Jensen DM, O’Leary JG, Pockros PJ, et al. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
